ADMA Biologics (ADMA) risk factors, FY2024 10-K

Risks Relating to our Business

1. 01Although we achieved net income on a GAAP basis for the year ended December 31, 2024 for the first time, we may not be able to maintain profitability andcontinue to generate positive cash flows in the future
2. 02Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations
3. 03our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers’ ability to maintain adequate quality control, quality assurance and qualified personnel
4. 04The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow at similar rates, if at all
5. 05Geopolitical and economic conditions, war, terrorism or other military actions may have a material adverse effect on our business
6. 06If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
7. 07Business interruptions could adversely affect our business
8. 08If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon development of such product, which would have a material adverse impact on our business
9. 09inability or unwillingness of medical investigators to follow our clinical protocols
10. 10If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon development of such product candidate altogether
11. 11Potential inability to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development
12. 12If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make it difficult for us to recover the costs of researching and developing such product candidate
13. 13diminish any competitive advantages that we may otherwise enjoy
14. 14Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review
15. 15With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring an adequate supply of high-titer antibody RSV plasma or balancing our research and development activities with our commercialization activities
16. 16We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for other pre and post-approval services, and such parties’ performance is, to some extent, outside of our control
17. 17We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from the FDA
18. 18Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and financial condition
19. 19widespread economic conditions or geopolitical conditions, including the exacerbated conflicts in Europe, the Middle East and the surrounding areas
20. 20Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products
21. 21If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired
22. 22The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all
23. 23Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements
24. 24The Ares Credit Facility is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any collateral
25. 25Developments by competitors may render our products or technologies obsolete or non-competitive
26. 26If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged
27. 27We could lose market exclusivity of a product earlier than expected
28. 28Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable terms or at all
29. 29If we are unable to successfully manage our growth, our business may be harmed
30. 30The loss of one or more key members of our management team could adversely affect our business
31. 31Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and reputation
32. 32If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed
33. 33We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits
34. 34Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us
35. 35The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities
36. 36Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing processes we have in place to counter transmittable diseases
37. 37We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma with proper specifications or other necessary raw materials
38. 38The biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products
39. 39The implementation of the Healthcare Reform Law in the United States may adversely affect our business
40. 40Corporate responsibility, specifically related to Environmental, Social and Governance (“ESG”) matters, may impose additional costs and expose us to new risks

Risks Relating to our Finances, Capital Requirements and Other Financial Matters

1. 41We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due
2. 42Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish proprietary rights
3. 43Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail
4. 44Our ability to use our net operating loss carryforwards (“NOLs”) may be limited
5. 45Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results
6. 46changes in U.S. federal, state and local tax rates, tax laws, regulations, or interpretations thereof
7. 47The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance
8. 48change in securities analysts’ estimates of our performance, or our failure to meet analysts’ expectations
9. 49Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock
10. 50authorization of the issuance of “blank check” preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders
11. 51We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain
12. 52Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of holders of our common stock